Covagen, Mitsubishi in deal for bispecific FynomAbs

Covagen AG (Zurich, Switzerland) will use its Fynomer protein engineering technology to develop bispecific

Read the full 147 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE